AngioDynamics, Inc.
ANGODrugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How ANGO's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Modified FOLFIRINOX Regimen | Phase 3 | Stage III Pancreatic Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in AngioDynamics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in AngioDynamics, Inc.'s (ANGO) pipeline across Phase 3. Its lead program is Modified FOLFIRINOX Regimen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AngioDynamics, Inc.'s next FDA catalyst?→
AngioDynamics, Inc.'s (ANGO) next tracked catalyst is a Earnings expected July 14, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ANGO biotech catalysts?→
Add ANGO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AngioDynamics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.